Novartis43m
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
UC San Diego Today45m
Xylazine Detected in U.S.-Mexico Border Drug Supply, Study Finds
New study confirms the presence of xylazine on the U.S.-Mexico border, posing numerous health risks for people in the region.
The Manila Times49m
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food ...